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ABSTRACT: This clinical paper reports the investigations conducted on a traditional African 
anti-asthmatic formulations and evaluates its toxicological and phyto-chemical effects. 
 
Introduction 
 
The traditional therapeutic approach to 
asthma included vinegar of squills, cow-
parship, mustard and round birthwort 
(Rosenblatt, 1976).  Datura stramonium has 
been used for the relief of asthma and 
bronchitis (Watt and Breyer-Brandwijk, 
1962; Lane and Storr, 1979).  The prolonged 
relief in bronchial asthma by Tylophora 
asthmatica has also been observed clinically 
(Haranath and Shyamala Kumani, 1975). 
 
Asthma is a disease characterized by an 
increase in airways resistance which is due 
to three main factors: (Rosenblat, 1976) 
contraction of the smooth muscle in the 
bronchioles; (Watt and Breyer-Brandwijk, 
1962) oedema of the bronchiolar mucosa; 
and increased bronchiolar secretions 
(Bowman and Rand, 1980).  Severe attacks 
of asthma are alarming and even if the 
thought of death itself is not necessarily 
threatening, inability to get enough air in 
and out of one’s lungs is a horrible and 
frightening experience, which provokes 
considerable anxiety (Lane and Storr, 1979). 
 
Drugs for therapy of asthma have multiplied 
over the past several years, but none is 
completely free of side effects (Poth, 
Haysman and Sieker, 1977 – 1978).  Infact, 
these conventional medicines only offer 
brief relief to the patients and therefore 
investigation into the traditional medicine 
prepared by Mr. Obuya is fundamental to 
the destiny of the asthmatics. 
 
We present here some of the preliminary 
findings of this traditional medicine. 
 
Materials and Methods 
 
Three traditional medicines were used in the 
study as shown in Table 1. 
 
Drug A and Drug B were prepared by 
boiling two plants each in a mixture 
involving water Drug C was also prepared 
as an aqueous extract. Pages  45– 51 
 
 
TABLE 1 
Various drug regimen preparations 
 
Preparation  Use 
Drug A 
Drug B 
Drug C 
For regular treatment 
For regular treatment 
For diagnosis 
 
Clinical Study 
 
In this pilot clinical study, we decided to 
observe a medicine man carrying out his 
treatment of asthma. 
 
About eleven patients, both males and 
females with ages ranging from 17 years to 
66 years were treated.  The recruitment of 
these patients was based on the fact that they 
were confirmed asthmatics attending a chest 
clinic who had given informed consent to 
participate. 
 
The initial treatment was started by the 
administration of the diagnostic medicine 
intranasally.  This resulted in profuse nasal 
mucous secretion and conjuctival injection.  
The oral medicine was administered soon 
after the initial procedure and thereafter the 
regular oral treatment was continued. 
 
Pulmonary function test was carried out on 
these patients prior to administration of the 
traditional medicine.  The test was repeated 
one hour after the administration of the 
medicines, then daily for two days and 
thereafter, every month. 
 
Toxicological Screening 
 
Female mice weighing 20g to 30g were 
used.  Various volumes of drug A and B 
were used. 
 
A group of six mice were injected 
intraperitoneally with drug B at a volume of 
0.4 ml.  The effect of the preparation on the 
animals was observed immediately after 
injection and within 36 hours.  The 
experiment was repeated with decreasing 
volumes of 0.2 ml and 0.05 ml. 
 
Drug A was  separated into fraction 1 and 
fraction 2.04 ml of fraction 1 was 
administered intraperitioneally to a group of 
mice and the effects observed immediately 
after injection and within 36 hours.  The 
experiment was repeated using various 
volumes of fraction 2. 
 
The control mice were injected 
intraperitoneally with normal saline at a 
volume of 0.4 ml and the effects observed as 
above. 
 
Phytochemical Screening 
 
The plant materials KOR 303, KOR 305 and 
KOR 379 were phyto-chemically screened. 
 
Results 
 
Clinical Study 
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The results of the clinical study are  presented in Tables 2 to 9. 
 
TABLE 2 
Patient 1: (F) (26 Years) 
 
Respiratory 
Function Index 
FVC  FEV  FEV % 
Baseline: 
 % Fred PFT 1/8/86 
% Change 4/8/86 
% Change 5/8/86 
% Change 6/8/86 
% Change 11/8/86 
% Change 10/9/86 
% Change 9/10/86 
% Change 5/11/86 
 
94 
1.2 
- 4.1 
- 4.9 
- 16.7 
+ 10.2 
- 3.5 
+ 2.6  
 
91 
0 
+ 0.7 
- 7.8 
+ 22.8 
+ 36.6 
- 7.3 
- 2.2 
 
-3 
+ 1.2 
+ 4.9 
- 11.6 
- 7.9 
+ 12.9 
- 3.8 
- 4.9 
 
 
 
TABLE 3 
Patient 2: (F) (51 Years) 
 
Respiratory 
Function Index 
FVC  FEV 1  FEV % 1 
Baseline: 
 % Fred PFT 1/8/86 
% Change 4/8/86 
% Change 5/8/86 
% Change 6/8/86 
% Change 11/8/86 
% Change 10/9/86 
% Change 9/10/86 
% Change 5/11/86 
 
17 
+ 323.5 
+ 16.2 
+ 6.8 
- 5.6 
+ 4.0 
0 
+ 0.8  
 
20 
+ 232.7 
+ 13.5 
+ 2.2 
- 5.3 
+ 7.8 
- 2.1 
- 0.5 
 
+13 
- 21.1 
- 1.3 
- 4.1 
0 
- 7.8 
- 2.1 
- 0.5 
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TABLE 4 
Patient 3: (M) (17 Years) 
 
Respiratory 
Function Index 
FVC  FEV 1  FEV % 1 
Baseline: 
 % Fred PFT 1/8/86 
% Change 4/8/86 
% Change 5/8/86 
% Change 6/8/86 
% Change 11/8/86 
% Change 10/9/86 
% Change 9/10/86 
% Change 5/11/86 
 
115 
- 3.5 
- 10.9 
+ 8.5 
- 1.8 
- 2.6 
- 6.5 
+ 8.0  
 
113 
- 17.9 
- 26.7 
- 60.4 
- 10.9 
- 32.8 
+ 36.2 
- 2.8 
 
- 2 
- 15.1 
- 17.8 
+ 38.3 
- 12.0 
- 31.2 
+ 26.1 
- 9.7 
 
 
 
TABLE 5 
Patient 4: (M) (24 Years) 
 
Respiratory 
Function Index 
FVC  FEV 1  FEV % 1 
Baseline: 
 % Fred PFT 1/8/86 
% Change 4/8/86 
% Change 5/8/86 
% Change 6/8/86 
% Change 11/8/86 
% Change 10/9/86 
% Change 9/10/86 
% Change 5/11/86 
 
66 
- 5.7 
+ 29.7 
+ 1.5 
+ 0.5 
+ 31.3 
- 2.1 
+ 7.3  
 
55 
+ 4.8 
+ 41.5 
+ 6.2 
+ 8.6 
+ 58.3 
- 1.1 
+ 12.8 
 
- 16 
+ 15.9 
+ 9.1 
+ 4.8 
+ 8.0 
+ 20.3 
+ 1.2 
+ 6 
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TABLE 6 
Patient 5: (M) (47 Years) 
 
Respiratory 
Function Index 
FVC  FEV 1  FEV % 1 
Baseline: 
 % Fred PFT 1/8/86 
% Change 4/8/86 
% Change 5/8/86 
% Change 6/8/86 
% Change 11/8/86 
% Change 10/9/86 
% Change 9/10/86 
% Change 5/11/86 
 
74 
- 59.5 
+ 162.9 
+ 125.8 
+ 19 
- 20.0 
- 2.1 
+ 3.7 
 
50 
- 28.7 
+ 53.8 
+ 12.0 
+ 46.8 
- 41.2 
- 32.8 
   + 5.2 
 
- 25 
+ 74.5 
- 41.7 
+ 3.6 
+ 24.1 
- 26.4 
+ 0.4 
+ 10.9 
 
 
 
TABLE 7 
Patient 6: (F) (43 Years) 
 
Respiratory 
Function Index 
FVC  FEV 1  FEV % 1 
Baseline: 
 % Fred PFT 1/8/86 
% Change 4/8/86 
% Change 5/8/86 
% Change 6/8/86 
% Change 11/8/86 
% Change 10/9/86 
% Change 9/10/86 
% Change 5/11/86 
 
78 
72.2 
0 
+ 4.8 
+ 2.6 
- 7.5 
- 6.5 
- 9.2 
 
63 
- 21.4 
- 0.9 
+ 10.6 
- 0.8 
+ 11.3 
- 16.7 
- 10.4 
 
- 16 
- 10.3 
0 
+ 4.9 
- 3.1 
+ 19.4 
- 10.8 
- 1.5 
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TABLE 8 
Patient 7: (F) (66 Years) 
 
Respiratory 
Function Index 
FVC  FEV 1  FEV % 1 
Baseline: 
 % Fred PFT 1/8/86 
% Change 4/8/86 
% Change 5/8/86 
% Change 6/8/86 
% Change 11/8/86 
% Change 10/9/86 
% Change 9/10/86 
% Change 5/11/86 
 
65 
-36.0 
- 2.67 
+ 9.6 
+ 57.5 
- 23 
+ 19.6 
- 
 
36 
- 36.4 
- 21.4 
+ 3.0 
+ 105.9 
- 37.1 
+ 43.2 
- 
 
- 28 
+ 3.7 
- 19.6 
- 4.4 
+ 30.2 
- 17.9 
+ 19.6 
- 
 
 
TABLE 9 
Patient 8: (M) (43 Years) 
 
Respiratory 
Function Index 
FVC  FEV 1  FEV % 1 
Baseline: 
 % Fred PFT 1/8/86 
% Change 4/8/86 
% Change 5/8/86 
% Change 6/8/86 
% Change 11/8/86 
% Change 10/9/86 
% Change 9/10/86 
% Change 5/11/86 
 
63 
- 6.0 
+ 29.4 
+ 12.8  
+ 17.9 
- 12.6 
- 28.9 
- 18.1 
 
39 
- 37.9 
- 46.0 
+ 29.8 
+ 77.0 
- 10.7 
- 47.2 
- 7.6 
 
- 31 
- 16.3 
- 22.0 
+ 12.5 
+ 52.8 
+ 2.0 
- 24 
+ 10.5 
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TABLE 10 
Patient 9: (F) (57 Years) 
 
Respiratory 
Function Index 
FVC  FEV 1  FEV % 1 
Baseline: 
 % Fred PFT 1/8/86 
% Change 4/8/86 
% Change 5/8/86 
% Change 6/8/86 
% Change 11/8/86 
% Change 10/9/86 
% Change 9/10/86 
% Change 5/11/86 
 
43 
- 10.7 
- 7.1 
- 20.3 
+ 19.4 
- 
- 
- 
 
29 
+ 10.3 
+ 24 
- 1.8 
+ 10.7 
- 
- 
- 
 
- 27 
0 
- 18.5 
22.7 
- 7.4 
- 
- 
- 
 
 
TABLE 11 
 
Patient  Self Evaluation  Clinician’s Evaluation 
1 
2 
3 
4 
5 
6 
7 
8 
9 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
Did not complete Treatment 
- 
- 
- 
+ 
+ 
± 
+ 
+ 
± 
 
Key:   + Definite Improvement 
  ± Some Degree of Improvement 
  - Inconclusive 
 
A summary of qualitative evaluation based on both subjective and objective observation is 
shown in Table 11. 
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Toxicological Screening 
 
Results of the toxicological screening in mice carried out on the two oral preparations are 
presented in Tables 12 and 13. 
 
TABLE 12 
Toxicological screening in mice drug A 
 
S. No.  Experiment  Vol. Injected 
I.P. (ml) 
Effects  Mortality after 
36 hours 
1  Fraction 1  0.4  - Flaccid behaviour 
- Mucoid excretion 
- Piloerection 
 
0 
- 
9 
2  Fraction 2  0.4  - Piloerection 
- Writhing reflex 
- Mucoid excretion 
- Gasping 
 
9 
- 
9 
3  Fraction 2  0.2  - Increased rate of breathing 
- Writhing reflex 
- Mucoid excretion 
- Gasping 
 
6 
- 
6 
4  Fraction 2  0.05  - Writhing reflex 
- Gasping 
- Mucoid excretion 
- Flaccid behaviour 
 
0 
- 
6 
5  Normal Saline  0.4  - No effect  0 
- 
6 
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TABLE 13 
Toxicological screening in mice drug B 
 
Experiment  Vol. Injected 
I.P. (ml) 
Effects  Mortality after 
36 hours 
1  0.4  - Writhing reflex 
- Mucoid excretion 
- Gasping 
 
6 
- 
6 
2  0.2  - Increased rate of breathing 
- Writhing reflex 
- Mucoid excretion 
 
3 
- 
6 
3  0.05  - Writhing reflex 
- Hind leg paralysis 
- Mucoid excretion 
 
0 
- 
6 
 
4  0.4  - No effect  0 
- 
6 
 
Phytochemical Screening 
 
The compounds detected in the plant materials are presented in Table 14. 
 
TABLE 14 
Phytochemical screening results 
 
Material  Alkaloids  Flavonoids  Triterpenes  Sterols  Cardiac 
Glycosides 
Anthra 
Quinones 
KOR 303 
KOR 305 
KOR 379 
+ 
+ 
+ 
- 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
- 
- 
- 
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DISCUSSION 
 
There are great advantages in the 
experimental asthma study of human 
subjects.  Not only does this method avoid 
extrapolation of results in animals to man, 
but in the field of respiration human subjects 
are the most verstatile because they can 
perform voluntary breathing maneuvers to 
suit  the purpose of the investigation 
(Bouhuys, 1976).  The pulmonary function 
tests carried out in our study plus the 
interviews indicated that great 
improvements were obtained using the 
traditional medicines.  We therefore feel that 
this traditional medicine has high potential 
and thus recommend further investigation. 
 
The narrow thereapeutic range obtained with 
some of the preparations in the toxicological 
evaluation in mice does not necessarily 
indicate toxicity in man as has been seen in 
the clinical study.  The species differences 
will therefore have to be considered. 
 
The preliminary phytochemical screening of 
the plant materials indicated that the major 
compounds are steroids.  Corticosteroids are 
frequently used as past of the treatment for 
patients with  bronchial asthma and are 
probably the most effective agents 
(McPhillips and Wilson).  There are several 
possible mechanisms which might account 
for the anti-asthmatic effects of 
corticosteroids.  These include inhibition of 
histamine formation or storage and the direct 
effect on smooth muscle by steroids. 
 
Corticosteroids under conventional use have 
vast side effects despite their greater potency 
and thus a safe and effective traditional 
medicine containing steroids would 
therefore be an ideal drug for the treatment 
of bronchial asthma. 
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